Assessment of Efficacy and Safety of Tegaserod Treatment and Placebo in Women With Dyspepsia
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This study is being done to evaluate the safety, tolerability and satisfactory relief of
dyspepsia symptoms in females excluding those with predominant stomach pain. Tegaserod will
be evaluated at 6mg twice daily and placebo.